



## **Corporate Press Release**

8<sup>th</sup> May 2013

### **Norgine Welcomes Their New Global Market Access Director**



Norgine are pleased to announce that Peter Conway joined the company on Monday 8<sup>th</sup> April 2013 as Global Market Access Director, in our Commercial Division. Peter has previously held national and international Market Access roles in Glaxo Wellcome, Wyeth and most recently Grünenthal.

Peter will be responsible for both marketed products and development projects to enable all appropriate patients access to Norgine's product portfolio, both now and in the future.

ENDS

#### **About Norgine**

Norgine is a successful, independent European specialty pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2012, Norgine's net product sales were c€250 million and the company employs over a 1,000 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology, critical and supportive care.

The Company currently markets a range of products in various markets in its key therapeutic areas: MOVICOL® for the treatment of constipation and faecal impaction, MOVIPREP® a bowel preparation for use prior to any procedure that requires a clean colon, KLEAN-PREP® for large bowel preparation prior to colonoscopy or surgery, XIFAXAN® (XIFAXANTA™) for the treatment of travellers' diarrhoea and the reduction in recurrence of episodes of overt hepatic encephalopathy, ORAMORPH® for the treatment of moderate to severe pain associated with cancer and our supportive care portfolio: SAVENE®, DANTRIUM®, XEROTIN® and PROTHER®

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, UK and Dreux, France. For more information: [www.norgine.com](http://www.norgine.com).

**Norgine Contact:**

Julie Hornby Winfield

Global Corporate Communications Manager

Tel: +44 1895 826600 or email to [jhornbywinfield@norgine.com](mailto:jhornbywinfield@norgine.com)

XIFAXAN is under licence from Alfa Wassermann S.p.A. XIFAXAN and TARGAXAN are registered trademarks of the Alfa Wassermann group of companies, licensed to the Norgine group of companies  
S2013May08.02